J Clin Invest. 2014 Jun;124(6):2355-63. doi: 10.1172/JCI72269. Epub 2014 Jun 2.
Acute kidney injury (AKI) remains a major clinical event with rising incidence, severity, and cost; it now has a morbidity and mortality exceeding acute myocardial infarction. There is also a documented conversion to and acceleration of chronic kidney disease to end-stage renal disease. The multifactorial nature of AKI etiologies and pathophysiology and the lack of diagnostic techniques have hindered translation of preclinical success. An evolving understanding of epithelial, endothelial, and inflammatory cell interactions and individualization of care will result in the eventual development of effective therapeutic strategies. This review focuses on epithelial and endothelial injury mediators, interactions, and targets for therapy.
急性肾损伤(AKI)仍然是一个主要的临床事件,其发病率、严重程度和成本都在上升;其发病率和死亡率现已超过急性心肌梗死。也有文献记载其会转化并加速慢性肾脏病进入终末期肾病。AKI 的病因和病理生理学的多因素性质以及缺乏诊断技术阻碍了临床前成功的转化。对上皮细胞、内皮细胞和炎症细胞相互作用的不断深入理解以及个体化治疗将最终导致有效治疗策略的发展。本综述重点介绍上皮细胞和内皮细胞损伤的介质、相互作用以及治疗靶点。